In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.
Ariey-Bonnet J, Carrasco K, Le Grand M, Hoffer L, Betzi S, Feracci M, Tsvetkov P, Devred F, Collette Y, Morelli X, Ballester P, Pasquier E
Biographie Moved my group to Imperial College in October 2022: https://ballestergroup.github.io/
Publications
Interpretable Machine Learning Models to Predict the Resistance of Breast Cancer Patients to Doxorubicin from Their microRNA Profiles.
Ogunleye AZ, Piyawajanusorn C, Gonçalves A, Ghislat G, Ballester PJ
Concise Polygenic Models for Cancer-Specific Identification of Drug-Sensitive Tumors from Their Multi-Omics Profiles.
Naulaerts S, Menden MP, Ballester PJ